How Has the Cell Free DNA (cfDNA) Testing Market Evolved Historically and What is its Current Size?
The cell free dna (cfdna) testing market has seen considerable growth due to a variety of factors.
• The cell free DNA (cfDNA) testing market has experienced exponential growth in recent years. It is expected to rise from $8.74 billion in 2024 to $10.86 billion in 2025, with a compound annual growth rate (CAGR) of 24.2%.
The historical growth is attributed to the rising adoption of cfDNA testing in prenatal care, increased use of cfDNA analysis, growing interest in cfDNA research across various medical fields, and the gaining approval of cfDNA tests by regulatory bodies.
What Is The Projected Growth Of The Cell Free DNA (cfDNA) Testing Template Market?
The cell free dna (cfdna) testing market is expected to maintain its strong growth trajectory in upcoming years.
• The cell-free DNA (cfDNA) testing market is expected to reach $25.56 billion by 2029 at a CAGR of 23.9%.
The growth is driven by personalized medicine, better healthcare infrastructure, an aging population, the rise in cancer cases, and the growing acceptance of liquid biopsy techniques. Trends include liquid biopsy adoption, Next-Generation Sequencing (NGS) advancements, AI and machine learning in testing, point-of-care cfDNA tests, and cloud-based platforms.
What Are The Key Drivers Fueling Growth In The Cell Free DNA (cfDNA) Testing Market?
The increasing prevalence of cancer is expected to propel the growth of the cell-free DNA (cfDNA) testing market. Cancer's rising prevalence is due to aging populations, environmental factors, and lifestyle changes. cfDNA testing helps detect genetic mutations linked to cancer early, allowing for early intervention and improved patient outcomes. For instance, in February 2024, the World Health Organization projected a 77% increase in cancer cases from 20 million in 2022 to 35 million in 2050. The growing cancer prevalence will fuel the demand for cfDNA testing.
What Are The Principal Market Segments In The Global Cell Free DNA (cfDNA) Testing Industry?
The cell free dna (cfDNA) testing market covered in this report is segmented –
1) By Product: Donor-Derived Cell-Free DNA, Circulating Cell-Free Tumor DNA, Cell-Free Fetal DNA
2) By Platforms: Next Generation Sequencing (NGS), rPCR And Multiplexed PCR, qPCR And dPCR, Other platforms
3) By Application: Oncology, Non-Invasive Prenatal Test (NIPT), Gynecology, Transplantation, Other Applications
Subsegments:
1) By Donor-Derived Cell-Free DNA: Organ Transplant Monitoring, Graft Rejection Detection
2) By Circulating Cell-Free Tumor DNA: Cancer Detection, Minimal Residual Disease Monitoring, Liquid Biopsy
3) By Cell-Free Fetal DNA: Non-Invasive Prenatal Testing (NIPT), Fetal Genetic Disorder Screening
Pre-Book The Cell Free DNA (cfDNA) Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Cell Free DNA (cfDNA) Testing Market?
Companies in the cell-free DNA (cfDNA) testing market are focusing on developing innovative technologies, such as liquid biopsy tests, which offer enhanced sensitivity, specificity, and efficiency in detecting cancer-related mutations and genetic alterations. Liquid biopsy tests enable oncologists to analyze circulating cfDNA released by tumor cells, helping in the creation of personalized therapy plans. For example, in May 2023, Labcorp, a US-based life sciences company, launched Labcorp Plasma Focus, a new liquid biopsy test for patients with advanced or metastatic solid tumors. This test is minimally invasive, uses a standard blood draw, and provides rapid results to identify clinically actionable biomarkers in various cancers, including lung, colorectal, breast, and melanoma.
Who Are the Key Players In The Cell Free DNA (cfDNA) Testing Market?
Major companies operating in the cell free DNA (cfDNA) testing market are:
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific Inc.
• Laboratory Corporation of America Holdings
• Quest Diagnostics Incorporated
• Agilent Technologies Inc.
• Illumina Inc.
• Qiagen N.V.
• Exact Sciences Corporation
• Bio-Techne Corporation
• Natera Inc.
• Myriad Genetics Inc.
• NeoGenomics Laboratories Inc.
• Invitae Corporation
• Foundation Medicine Inc.
• Guardant Health Inc.
• Integrated DNA Technologies Inc.
• Caris Life Sciences Inc.
• Twist Bioscience Corporation
• Adaptive Biotechnologies Corporation
• Biodesix Inc.
• Biocept Inc.
• Personal Genome Diagnostics Inc.
• Agena Bioscience Inc.
• Menarini Silicon Biosystems Inc.
• Circulogene Theranostics LLC
What Are The Regional Insights Into The Cell Free DNA (cfDNA) Testing Market?
North America was the largest region in the cell-free DNA (cfDNA) testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell free DNA (cfDNA) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
